These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38777171)

  • 1. MetALD: The Outcome of Living Under the Shadow of Alcohol for 4 Decades.
    Méndez-Sánchez N; Ramírez-Mejía MM
    Clin Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38777171
    [No Abstract]   [Full Text] [Related]  

  • 2. A novel experimental model of MetALD in male mice recapitulates key features of severe alcohol-associated hepatitis.
    Babuta M; Morel C; de Carvalho Ribeiro M; Datta AA; Calenda C; Copeland C; Nasser I; Szabo G
    Hepatol Commun; 2024 Jul; 8(7):. PubMed ID: 38896082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups.
    Fukuda T; Okamoto T; Fukaishi T; Kawakami A; Tanaka M; Yamada T; Monzen K
    Front Endocrinol (Lausanne); 2024; 15():1392280. PubMed ID: 38779448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chrysanthemum morifolium attenuates metabolic and alcohol-associated liver disease via gut microbiota and PPARα/γ activation.
    Liu D; Zhan J; Wang S; Chen L; Zhu Q; Nie R; Zhou X; Zheng W; Luo X; Wang B; Nie J; Ye X
    Phytomedicine; 2024 Jul; 130():155774. PubMed ID: 38820659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MetALD: Does it require a different therapeutic option?
    Marek GW; Malhi H
    Hepatology; 2024 May; ():. PubMed ID: 38820071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort.
    Oh JH; Ahn SB; Cho S; Nah EH; Yoon EL; Jun DW
    J Hepatol; 2024 Nov; 81(5):772-780. PubMed ID: 38879175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Waitlisting and liver transplantation for MetALD in the United States: An analysis of the UNOS national registry.
    Ochoa-Allemant P; Serper M; Wang RX; Tang H; Ghandour B; Khan S; Mahmud N
    Hepatology; 2024 Apr; ():. PubMed ID: 38683569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence.
    Ciardullo S; Mantovani A; Morieri ML; Muraca E; Invernizzi P; Perseghin G
    Liver Int; 2024 Aug; 44(8):1762-1767. PubMed ID: 38597738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study.
    Israelsen M; Torp N; Johansen S; Hansen CD; Hansen ED; Thorhauge K; Hansen JK; Villesen I; Bech K; Wernberg C; Andersen P; Lindvig KP; Tsochatzis EA; Thiele M; Rinella ME; Krag A;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):218-228. PubMed ID: 38218202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
    Kwak M; Kim HS; Jiang ZG; Yeo YH; Trivedi HD; Noureddin M; Yang JD
    Hepatology; 2024 May; ():. PubMed ID: 38739848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
    Ochoa-Allemant P; Marrero JA; Serper M
    Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study.
    Yun B; Park H; Ahn SH; Oh J; Kim BK; Yoon JH
    Am J Gastroenterol; 2024 Jun; ():. PubMed ID: 38934496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality.
    Tamaki N; Kimura T; Wakabayashi SI; Umemura T; Kurosaki M; Loomba R; Izumi N
    Aliment Pharmacol Ther; 2024 Jul; 60(1):61-69. PubMed ID: 38664876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study.
    Moon JH; Jeong S; Jang H; Koo BK; Kim W
    EClinicalMedicine; 2023 Nov; 65():102292. PubMed ID: 37954905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
    Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
    Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups.
    Li M; Chen W; Deng Y; Xie W
    Nutr Metab Cardiovasc Dis; 2024 Sep; 34(9):2085-2094. PubMed ID: 38902191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population.
    Schneider CV; Schneider KM; Raptis A; Huang H; Trautwein C; Loomba R
    Aliment Pharmacol Ther; 2024 May; 59(10):1271-1281. PubMed ID: 38500443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease.
    Israelsen M; Torp N; Johansen S; Thiele M; Krag A
    Lancet Gastroenterol Hepatol; 2023 Oct; 8(10):866-868. PubMed ID: 37567208
    [No Abstract]   [Full Text] [Related]  

  • 20. Effectiveness of 1-year pemafibrate treatment on steatotic liver disease: the influence of alcohol consumption.
    Iwasa M; Sugimoto R; Eguchi A; Tamai Y; Shigefuku R; Fujiwara N; Tanaka H; Kobayashi Y; Ikoma J; Kaito M; Nakagawa H
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):793-801. PubMed ID: 38526942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.